Clinical Trials

Sponsor: MUSC

Sponsor Study ID: 103352

Study Title: Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial

CTO #: 103352

NCT Number: NCT05036226

Phase: I/II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Larynx, Other Female Genital, Prostate, Lip, Oral Cavity and Pharynx

Study Objectives: Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.

Study Documents    
(MUSC NetID required for document access)